The Daily Biotech Pulse: AbbVie’s Rinvoq Gets Label Expansion, AstraZeneca COVID Antibody Cocktail Authorized By UK Regulator, Stealth Touts Positive Data
Here's a roundup of top developments in the biotech space over the last 24 hours:
Recap: X4 Pharmaceuticals Q4 Earnings
X4 Pharmaceuticals (NASDAQ:XFOR) reported its Q4 earnings results on Thursday, March 17, 2022 at 08:00 AM.
Here's what investors need to know about the announcement.
X4 Pharmaceuticals Q4 EPS $(1.24) Down From $(0.91) YoY
X4 Pharmaceuticals (NASDAQ:XFOR) reported quarterly losses of $(1.24) per share. This is a 36.26 percent decrease over losses of $(0.91) per share from the same period last year.
Earnings Preview For X4 Pharmaceuticals
X4 Pharmaceuticals (NASDAQ:XFOR) is set to give its latest quarterly earnings report on Thursday, 2022-03-17. Here's what investors need to know before the announcement.
Analysts estimate that X4 Pharmaceuticals will report an earnings per share (EPS) of $-0.68.
The Week Ahead In Biotech (March 13-19): Bristol-Myers Squibb’s Melanoma Drug Decision, Multiple Conference Presentations And Earnings Dominate Proceedings
Biotech stocks pulled back for a second week running, as the Ukraine war cast its cloud on the broader market. Dwindling earnings news flow and company-specific developments served as catalysts during the week.
28 Stocks Moving In Friday’s Mid-Day Session
Gainers
Genfit SA (NASDAQ: GNFT) shares jumped 33.6% to $4.41 after the company, and Ipsen, announced an exclusive licensing agreement for elafibranor.
58 Biggest Movers From Yesterday
Gainers
Adagio Therapeutics, Inc. (NASDAQ: ADGI) shares jumped 123.3% to settle at $14.18 on Thursday after traders circulated rumors of a reiterated Buy rating and $46 price target from Jefferies.